Based on the provided paper content, I will answer the questions as instructed. Here are the answers:

"""
Question: 1101

Evidence: All French HIV-2 sequences used in this study have been de- posited on GenBank: KP226396-KP226481 and MW697236- MW697343 (pol); MW697344-MW697444 (env); KP226314- KP226501 (vif); and MW714050-MW714124 (LTR).

Rationale: The paper explicitly states that all French HIV-2 sequences used in the study have been deposited in GenBank and provides the specific accession numbers. This indicates that the paper reports previously unpublished data from the French ANRS CO5 HIV-2 cohort.

Answer: Yes
"""

"""
Question: 1102

Evidence: We collected 444 pol, 152 vif, 129 env, and 74 LTR sequences from patients of the French ANRS CO5 HIV- 2 cohort completed by 221 pol, 18 vif, 377 env, and 63 LTR unique sequences from public databases.

Rationale: The paper describes collecting numerous sequences (pol, vif, env, LTR) from HIV-2 patients and public databases, confirming it reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper content does not contain any mention of in vitro passage experiments.

Rationale: After thoroughly reading the entire paper content, I found no references to in vitro passage experiments being conducted or reported.

Answer: No
"""

"""
Question: 1104

Evidence: The paper content does not contain any mention of in vitro antiretroviral susceptibility data.

Rationale: After thoroughly reading the entire paper content, including methods and results sections, I found no references to in vitro antiretroviral susceptibility testing or data.

Answer: No
"""

"""
Question: 2101

Evidence: All French HIV-2 sequences used in this study have been de- posited on GenBank: KP226396-KP226481 and MW697236- MW697343 (pol); MW697344-MW697444 (env); KP226314- KP226501 (vif); and MW714050-MW714124 (LTR).

Rationale: The paper explicitly provides GenBank accession numbers for the sequenced HIV isolates from the French cohort.

Answer: Yes
"""

"""
Question: 2102

Evidence: All French HIV-2 sequences used in this study have been de- posited on GenBank: KP226396-KP226481 and MW697236- MW697343 (pol); MW697344-MW697444 (env); KP226314- KP226501 (vif); and MW714050-MW714124 (LTR).

Rationale: The provided GenBank accession numbers are for sequences from the French ANRS CO5 HIV-2 cohort, which are clinical isolates from patients, not laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: All French HIV-2 sequences used in this study have been de- posited on GenBank: KP226396-KP226481 and MW697236- MW697343 (pol); MW697344-MW697444 (env); KP226314- KP226501 (vif); and MW714050-MW714124 (LTR).

Rationale: The paper explicitly lists the GenBank accession numbers for the French HIV-2 sequences across different genomic regions.

Answer: KP226396-KP226481 and MW697236-MW697343 (pol); MW697344-MW697444 (env); KP226314-KP226501 (vif); and MW714050-MW714124 (LTR)
"""

"""
Question: 2202

Evidence: The paper content does not contain any mention of lists of mutations for individual sequenced HIV isolates.

Rationale: After thoroughly reading the entire paper content, I found no references to specific mutation lists for individual HIV isolates.

Answer: No
"""

"""
Question: 2301

Evidence: Genetic diversity of HIV-2 groups A and B has not yet been fully described.

Rationale: The paper focuses exclusively on HIV-2, specifically groups A and B, throughout the entire content.

Answer: HIV-2
"""

"""
Question: 2302

Evidence: We observed the existence of two distinct lineages within HIV-2 group A, herein called A1 and A2. HIV-2 group B started to diverge in 1961 (1952--70).

Rationale: The paper clearly identifies and describes two distinct lineages within HIV-2 group A (A1 and A2) and also includes HIV-2 group B.

Answer: HIV-2 group A (with sub-lineages A1 and A2) and HIV-2 group B
"""

"""
Question: 2303

Evidence: These comprised a total of 444 partial pol (encompassing the full protease (PR) and partial reverse transcriptase (RT) genes; 1,350 nt) sequences, 129 partial env (V3 loop; 525 nt) sequences, 152 complete vif (655 nt) sequences and 74 long terminal repeats (LTR; 526 nt) sequences.

Rationale: The methods section explicitly lists the HIV genes that were sequenced: pol (including protease and reverse transcriptase), env (V3 loop region), vif, and LTR.

Answer: pol, env, vif, and LTR
"""

"""
Question: 2304

Evidence: These comprised a total of 444 partial pol (encompassing the full protease (PR) and partial reverse transcriptase (RT) genes; 1,350 nt) sequences from 291 patients.

Rationale: The paper explicitly states that pol sequences were obtained and analyzed from HIV-2 patients.

Answer: Yes
"""

"""
Question: 2401

Evidence: The HIV-2 epidemic in coastal Western African countries (i.e. Cape Verde, Senegal, Gambia, Guinea Bissau and Guinea) was dominated by lineage A1. Inversely, inland western countries (i.e. Mali and Burkina-Faso) and coastal Southern countries (i.e. Ivory Coast, Ghana, Togo, Nigeria and Cameroon) were dominated by A2 and B lineages.

Rationale: The results section provides detailed geographical distribution of HIV-2 lineages across multiple West African countries.

Answer: Coastal Western African countries: Cape Verde, Senegal, Gambia, Guinea Bissau, Guinea; Inland western countries: Mali, Burkina-Faso; Coastal Southern countries: Ivory Coast, Ghana, Togo, Nigeria, Cameroon; Also Portugal and France.
"""

"""
Question: 2402

Evidence: The paper content does not contain specific information about the years when sequenced samples were obtained.

Rationale: While the paper discusses estimated divergence times and epidemiological trends over decades, it does not provide specific years when the actual sequenced samples were collected from patients.

Answer: NA
"""

"""
Question: 2502

Evidence: The paper content does not explicitly specify the sequencing methodology used.

Rationale: After thoroughly reading the methods section and entire paper content, I found no explicit mention of whether Sanger sequencing or any other specific sequencing technology was used.

Answer: NA
"""

"""
Question: 2503

Evidence: The paper content does not explicitly specify the sequencing methodology used.

Rationale: After thoroughly reading the methods section and entire paper content, I found no explicit mention of whether NGS technology or any other specific sequencing technology was used.

Answer: NA
"""

"""
Question: 2504

Evidence: The paper content does not contain any mention of cloning prior to sequencing.

Rationale: After thoroughly reading the entire paper content, including the methods section, I found no references to cloning procedures before sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: The paper content does not contain any mention of single genome sequencing.

Rationale: After thoroughly reading the entire paper content, I found no references to single genome sequencing being performed.

Answer: No
"""

"""
Question: 2506

Evidence: The paper content does not contain any mention of molecular cloning.

Rationale: After thoroughly reading the entire paper content, I found no references to molecular cloning procedures.

Answer: No
"""

"""
Question: 2601

Evidence: The paper content does not specify whether sequencing was performed on plasma virus or PBMC virus.

Rationale: After thoroughly reading the entire paper content, I found no explicit information about the source of sequenced virus (plasma vs PBMC).

Answer: NA
"""

"""
Question: 2602

Evidence: The paper content does not specify whether sequencing was performed on plasma virus or PBMC virus.

Rationale: After thoroughly reading the entire paper content, I found no explicit information about the source of sequenced virus (plasma vs PBMC).

Answer: NA
"""

"""
Question: 2603

Evidence: The paper content does not specify the number of samples that underwent plasma virus sequencing.

Rationale: After thoroughly reading the entire paper content, I found no information about plasma virus sequencing or the number of samples processed this way.

Answer: NA
"""

"""
Question: 2604

Evidence: The paper content does not specify the number of samples that underwent PBMC virus sequencing.

Rationale: After thoroughly reading the entire paper content, I found no information about PBMC virus sequencing or the number of samples processed this way.

Answer: NA
"""

"""
Question: 2605

Evidence: The paper content does not contain explicit information about whether sequences were obtained from individuals with active HIV replication.

Rationale: While the paper discusses viral loads and clinical characteristics, it does not explicitly state whether sequenced viruses came from individuals with active HIV replication.

Answer: NA
"""

"""
Question: 2606

Evidence: The paper content does not contain any mention of proviral DNA reservoir sequencing.

Rationale: After thoroughly reading the entire paper content, I found no references to sequencing from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701

Evidence: The paper content does not contain any specific information about samples obtained from infants or children.

Rationale: After thoroughly reading the entire paper content, including the patient characteristics table, I found no mention of pediatric patients or samples from infants/children.

Answer: No
"""

"""
Question: 2702

Evidence: The paper content does not contain any mention of clinical trials.

Rationale: After thoroughly reading the entire paper content, I found no references to patients being enrolled in clinical trials.

Answer: No
"""

"""
Question: 2703

Evidence: The paper content does not contain any mention of clinical trials.

Rationale: After thoroughly reading the entire paper content, I found no references to any patients being enrolled in clinical trials.

Answer: No
"""

"""
Question: 3101

Evidence: These comprised a total of 444 partial pol sequences from 291 patients, 129 partial env sequences from 106 unique patients, 152 complete vif sequences from 147 patients and 74 long terminal repeats (LTR) sequences from 74 patients.

Rationale: The methods section provides specific numbers of patients from whom sequences were obtained for different genomic regions.

Answer: For pol sequences: 291 patients; for env sequences: 106 patients; for vif sequences: 147 patients; for LTR sequences: 74 patients (with some overlap between datasets)
"""

"""
Question: 3102

Evidence: The paper content does not specify whether all individuals in the study underwent HIV sequencing.

Rationale: While the paper provides numbers of patients with sequences for different genomic regions, it does not explicitly state whether all individuals in the cohort underwent sequencing.

Answer: NA
"""

"""
Question: 4101

Evidence: The paper content does not contain explicit information about the ART status of individuals.

Rationale: After thoroughly reading the entire paper content, including the methods and results sections, I found no explicit information about whether individuals were ART-naive.

Answer: NA
"""

"""
Question: 4102

Evidence: The paper content does not contain explicit information about the ART status of individuals.

Rationale: After thoroughly reading the entire paper content, I found no explicit information about whether individuals had previously received ARV drugs.

Answer: NA
"""

"""
Question: 4103

Evidence: The paper content does not contain explicit information about the ART status of individuals.

Rationale: After thoroughly reading the entire paper content, I found no explicit information about the ART status of individuals, either naive or experienced.

Answer: NA
"""

"""
Question: 4104

Evidence: The paper content does not contain information about the number of samples from ART-naive individuals.

Rationale: After thoroughly reading the entire paper content, I found no information about ART-naive individuals or counts of such samples.

Answer: NA
"""

"""
Question: 4105

Evidence: The paper content does not contain complete ART history information for all individuals.

Rationale: After thoroughly reading the entire paper content, including the patient characteristics table, I found no comprehensive ART history information provided for the study participants.

Answer: No
"""

"""
Question: 4201

Evidence: The paper content does not contain any mention of transmitted HIV drug resistance.

Rationale: After thoroughly reading the entire paper content, I found no references to transmitted HIV drug resistance or its prevalence.

Answer: No
"""

"""
Question: 4202

Evidence: The paper content does not contain any mention of pretreatment HIV drug resistance.

Rationale: After thoroughly reading the entire paper content, I found no references to pretreatment HIV drug resistance or its prevalence.

Answer: No
"""

"""
Question: 4301

Evidence: The paper content does not contain information about specific drug classes received by individuals.

Rationale: After thoroughly reading the entire paper content, I found no information about antiretroviral drug classes that individuals may have received.

Answer: NA
"""

"""
Question: 4302

Evidence: The paper content does not contain any mention of integrase inhibitors.

Rationale: After thoroughly reading the entire paper content, I found no references to integrase inhibitors or individuals receiving them.

Answer: No
"""

"""
Question: 4303

Evidence: The paper content does not contain explicit information about protease inhibitors.

Rationale: While the paper sequences the protease gene region, it does not provide information about whether individuals received protease inhibitors as treatment.

Answer: NA
"""

"""
Question: 4304

Evidence: The paper content does not contain information about whether all individuals received the same ART.

Rationale: After thoroughly reading the entire paper content, I found no information about ART regimens or whether they were consistent across individuals.

Answer: NA
"""

"""
Question: 4305

Evidence: The paper content does not contain any mention of integrase strand transfer inhibitors (INSTIs).

Rationale: After thoroughly reading the entire paper content, I found no references to INSTIs or whether individuals were INSTI-naive.

Answer: NA
"""

"""
Question: 4403

Evidence: The paper content does not contain information about the number of ART regimens individuals received.

Rationale: After thoroughly reading the entire paper content, I found no information about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4404

Evidence: The paper content does not contain information about the number of ART regimens individuals received.

Rationale: After thoroughly reading the entire paper content, I found no information about individuals receiving more than two ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: The paper content does not contain information about whether all individuals received the same number of ART regimens.

Rationale: After thoroughly reading the entire paper content, I found no information about the number of ART regimens or whether this was consistent across individuals.

Answer: NA
"""

"""
Question: 4406

Evidence: The paper content does not contain information about whether all individuals received one ART regimen.

Rationale: After thoroughly reading the entire paper content, I found no information about ART regimens or whether all individuals received only one regimen.

Answer: NA
"""

"""
Question: 4501

Evidence: The paper content does not contain any mention of dolutegravir.

Rationale: After thoroughly reading the entire paper content, I found no references to dolutegravir or individuals receiving it.

Answer: NA
"""

"""
Question: 4502

Evidence: The paper content does not contain any mention of darunavir.

Rationale: After thoroughly reading the entire paper content, I found no references to darunavir or individuals receiving it.

Answer: NA
"""

"""
Question: 5101

Evidence: The paper content does not contain information about drug resistance mutations in individuals.

Rationale: After thoroughly reading the entire paper content, I found no information about drug resistance mutations or counts of individuals with such mutations.

Answer: NA
"""

"""
Question: 5102

Evidence: The paper content does not contain any mention of INSTI-resistance mutations.

Rationale: After thoroughly reading the entire paper content, I found no references to INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 5103

Evidence: The paper content does not contain any mention of TDF-resistance mutations.

Rationale: After thoroughly reading the entire paper content, I found no references to TDF (tenofovir) resistance mutations.

Answer: NA
"""

"""
Question: 5104

Evidence: The paper content does not contain any mention of INSTI-resistance mutations.

Rationale: After thoroughly reading the entire paper content, I found no references to specific INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 6101

Evidence: The paper content does not contain any mention of phenotypic susceptibility testing methods.

Rationale: After thoroughly reading the entire paper content, I found no references to phenotypic susceptibility testing being performed.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper content does not contain any mention of IC values like IC50 or IC90.

Rationale: After thoroughly reading the entire paper content, I found no references to IC50, IC90, or similar inhibitory concentration values.

Answer: No
"""

"""
Question: 6103

Evidence: The paper content does not contain any mention of IC50 fold change values.

Rationale: After thoroughly reading the entire paper content, I found no references to IC50 fold change values.

Answer: No
"""

"""
Question: 6104

Evidence: The paper content does not contain any mention of phenotypic susceptibility assays.

Rationale: After thoroughly reading the entire paper content, I found no references to phenotypic susceptibility assays being used.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper content does not contain any mention of replication capacity data.

Rationale: After thoroughly reading the entire paper content, I found no references to replication capacity testing or data.

Answer: No
"""

"""
Question: 6106

Evidence: The paper content does not contain any mention of drugs tested in phenotypic susceptibility assays.

Rationale: After thoroughly reading the entire paper content, I found no references to specific drugs being tested in phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper content does not contain any mention of site-directed mutations.

Rationale: After thoroughly reading the entire paper content, I found no references to site-directed mutations in isolates.

Answer: No
"""

"""
Question: 7102

Evidence: The paper content does not contain any mention of in vitro passage experiments.

Rationale: After thoroughly reading the entire paper content, I found no references to in vitro passage experiments being conducted.

Answer: No
"""